Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Feb 5:11:2040622319899297.
doi: 10.1177/2040622319899297. eCollection 2020.

Emerging treatments for inflammatory bowel disease

Karl Hazel  1 , Anthony O'Connor  2
Affiliations
Review

Emerging treatments for inflammatory bowel disease

Karl Hazel et al. Ther Adv Chronic Dis. .

Abstract

Inflammatory bowel disease (IBD), including Crohn's disease (CD) and ulcerative colitis (UC), is characterized by chronic inflammation, a relapsing and remitting clinical course, requirement for lifelong medication and often, significant morbidity. While multiple effective therapeutic options exist for the treatment of IBD, a proportion of patients will either fail to respond or lose response to therapy. Advances in therapeutics, such as the gut-specific anti-integrins, now offer patients an alternative option to systemic immunosuppression. Anti-interleukin 12 (anti-IL-12)/IL-23 agents offer new and effective treatment options for CD, while the oral small molecules now offer an oral alternative for the treatment of moderate-to-severe disease, previously requiring subcutaneous injection or intravenous infusion. Alternatives to pharmacological treatment such as stem-cell transplant and faecal microbiota transplant are also showing some promise in the treatment of both CD and UC.

Keywords: Crohn’s disease; inflammatory bowel disease; ulcerative colitis.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement: AOC has received speaker and advisory board fees from MSD Human Health, Abbvie, Takeda and Janssen Pharmaceuticals.

Figures

Figure 1.
Figure 1.
The inflammatory cascade in inflammatory bowel disease. IFNγ, interferon gamma; IL, interleukin; Th, T-helper cell; TLR, toll-like receptor; TNF, tumour necrosis factor.
See this image and copyright information in PMC

References

    1. Khalili H, Chan S, Lochhead P, et al. The role of diet in the aetiopathogenesis of inflammatory bowel disease. Nat Rev Gastroenterol Hepatol 2018; 15: 525–535. - PMC - PubMed
    1. Harris M, Hartman D, Lemos B, et al. AVX-470, an orally delivered anti-tumour necrosis factor antibody for treatment of active ulcerative colitis: results of a first-in-human trial. J Crohn’s Colitis 2016; 10: 631–640. - PubMed
    1. Guagnozzi D, Caprilli R. Natlaizumab in the treatment of Crohn’s disease. Biologics 2008; 2: 275–284. - PMC - PubMed
    1. Berlin C, Berg E, Briskin M. α4β7 integrin mediates lymphocyte bindings to the mucosal vascular addressin MAdCAM–1. Cell 1993; 74: 185–195. - PubMed
    1. Vermiere S, O’Byrne S, Keir M, et al. Etrolizumab as induction therapy for ulcerative colitis: a randomized, controlled, phase 2 trial. Lancet 2014; 384: 309–318. - PubMed

LinkOut - more resources